IITRI Announces Expansion of Immunology Capabilities

IITRI is pleased to announce the expansion of our infectious disease immunology capabilities with the recent hiring of Justin Richner, PhD, to the position of Research Biologist, Viral Immunology. Dr. Richner’s research focus includes viral pathogenesis and host...
IITRI Chosen As Member of Nonclinical Studies Network

IITRI Chosen As Member of Nonclinical Studies Network

IITRI was one of 7 organizations chosen as a member of a Nonclinical Studies Network created by BARDA to aid in the successful development of medical countermeasures for biological threats. Nonclinical studies supporting treatments for biological threats is especially...
IITRI at IMED Meeting on Zika Mouse and Macaques Models

IITRI at IMED Meeting on Zika Mouse and Macaques Models

IITRI will be presenting at the upcoming International Meeting on Emerging Diseases and Surveillance (IMED) November 4-7, 2016 in Vienna, Austria, on Zika Mouse and Macque Models developed by our Molecular and Microbiology team. For more details, please contact us....
IITRI Awarded Over $4.7M BARDA Contracts

IITRI Awarded Over $4.7M BARDA Contracts

IITRI announces the recent award of three major new programs by the Biomedical Advanced Research and Development Authority (BARDA) valued at more than $4.7 M. The programs are for the development and/or evaluation of cutting edge technologies and agents to control...

NCI Awards IITRI $29.8 Million for Two New Preclinical Programs

The National Cancer Institute’s Division of Cancer Treatment and Diagnosis (DCTD) has awarded IITRI $29.8 million for two major 5-year new programs. The DCTD supports many programs that facilitate the development of cancer therapeutics from the bench to the patient,...